$FDMT SEC Filings

Received 1,635 shares by exercise or conversion ($6.77K) · Sold 1,635 shares ($21K)

Sold 58,333 shares ($754K)

On September 28, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular...

Received 1,635 shares by exercise or conversion ($6.77K) · Sold 1,635 shares ($22.3K)

Sold 58,333 shares ($811K)

Received 584 shares by exercise or conversion ($3.79K) · Sold 584 shares ($8.18K)

Received 50,000 shares by exercise or conversion ($207K) · Sold 69,076 shares ($1.09M)

Received 1,635 shares by exercise or conversion ($6.77K) · Sold 1,635 shares ($19.6K) · Received 1,635 shares by exercise or conversion ($6.77K) · 1 more

Sold 26,842 shares ($275K)

Sold 12,415 shares ($125K)